Human herpesvirus 8 is a gammaherpesvirus which may be implicated in the pathogenesis of multiple myeloma. Viral DNA sequences have been found in the bone marrow, peripheral blood and leukapheresis products of myeloma patients. These findings have significant implications for the use of leukapheresed cells in the transplantation and immunotherapy of myeloma. The studies suggest the cell which harbours the virus may be dendritic in origin. We have previously reported that dendritic cells cultured for use in the clinical setting do not harbour HHV-8. In this study, we examined the leukapheresis products of a larger cohort of myeloma patients for the presence of HHV-8 using a highly sensitive PCR technique. A strong association between HHV-8 and myeloma was not confirmed, with only 4% of the patient samples positive for viral sequences. While further study is needed, the current use of apheresis cells and their cultured progeny in the treatment of myeloma should not be compromised.
HHV-8 is a gammaherpesvirus 1 which has been strongly implicated in the development of Kaposi's sarcoma 2 and primary effusion lymphoma. 3 There has been considerable interest in this virus recently following a report suggesting that it may be implicated in the pathogenesis of multiple myeloma. 4 HHV-8 DNA sequences were found in cells derived from the bone marrow stromal cultures of patients with myeloma. These cells had features suggesting they may be of dendritic origin. It was postulated that HHV-8-infected dendritic cells (DC) could support myeloma cell growth by the production of a homologue of human interleukin-6 (vIL-6). Human IL-6 is a growth factor for myeloma cells 5, 6 and the viral homologue encoded by HHV-8 is also capable of supporting myeloma cell growth. 7 Subsequent reports have identified HHV-8 DNA sequences in fresh bone marrow biopsies 8 (by in situ hybridisation and PCR) and the peripheral blood 9 and leukapheresis products 10 (by PCR) of myeloma patients.
These findings are of great potential importance regarding the oncogenesis of myeloma but also have implications for the management of this disease. Firstly, if stem cell collections used for autologous transplantation are contaminated with HHV-8-infected cells which stimulate myeloma cell growth, consideration needs to be given to methods to purge these cells from the graft. Secondly, DC cultured from blood and leukapheresis products are being used in clinical immunotherapy programs for a number of human cancers, including myeloma. 11 Tarte et al 12 have recently reported that clinical grade functional DC from myeloma patients are not infected with HHV-8. They found that the DC, in addition to the apheresis cells and purified CD34 cells from which they were cultured, in 10 of 11 patients with myeloma were negative for HHV-8 DNA sequences. We have also published a similar study demonstrating that DC cultured from mononuclear cells and CD34 cells do not harbour HHV-8. 13 In our study, the leukapheresis products from which the DC were cultured were not analysed and it is possible that the culture procedure used excluded a cell which may harbour the virus. Therefore, we examined the leukapheresis products of 51 myeloma patients undergoing stem cell collection for autologous transplantation for the presence of HHV-8 DNA sequences using a highly sensitive PCR technique.
Materials and methods

Patients
Fifty-one patients diagnosed with multiple myeloma between March 1993 and December 1997 underwent stem cell collection for autologous transplantation. There were 32 males and 19 females. The median age was 57 years (range 39-68). The median stage of disease at time of transplantation was Salmon-Durie stage 1 (range 1-3). All patients were leukapheresed following stem cell mobilisation with cyclophosphamide (3 g/m 2 ) and G-CSF 300 g daily, as previously described. 14 
Leukapheresis samples
Aliquots of cryopreserved leukapheresis product from each patient were thawed and the red cells removed via ammonium chloride lysis. No other manipulation of the sample was performed. Aliquots of 2 × 10 6 cells were used for DNA extraction.
Polymerase chain reaction
DNA was extracted with the Nucleon genomic purification kit (Scotlab, Strathclyde, UK) according to manufacturer's instructions and 0.5-1.0 g of DNA, representing approximately 200 000 cells, was used as a template in a nested PCR assay. First round amplification was performed using primers to amplify the KS330 233 DNA sequence of HHV-8. 1 The primers were 5Ј-AGCCGAAAGGATTCCAC-CATT-3Ј and 5Ј-TCCGTGTTGTCTACGTCCAGA-3Ј. The DNA was suspended in a volume of 25 l in the presence of , 10 and 1 copy of the HHV-8 genome, were analysed using the same nested PCR assay described above. All DNA samples were also amplified by PCR for human ␤-globin sequences to ensure integrity of the samples.
Results
PCR for HHV-8
In dilutional series of positive control DNA from the BCP-1 cell line, the first round of amplification was able to detect the equivalent of 10 copies of HHV-8 genome. After second round amplification, the nested PCR was consistently able to detect the equivalent of 1 copy of HHV-8 genome. Of the 51 leukapheresis products analysed, two were positive for the presence of HHV-8 on duplicate testing (Figure 1 ). Both of these samples were negative after first round amplification but demonstrated a clear signal after second round amplification. All patient samples were positive by PCR for the presence of ␤-globin. Of particular interest, one of the positive leukapheresis samples was a patient whose DC cultured from the same leukapheresis product were negative for HHV-8 on repeat testing in our previous study.
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Discussion
Our results demonstrate a low incidence (4%) of HHV-8 in the leukapheresis products of myeloma patients and contrast with the incidence of 48% reported by Vescio et al. 10 This incidence is consistent with the reported seroprevalence of HHV-8 in the UK, both within the general popu- show the 191 bp second round product from the two positive patients. Lanes 7, 9 and 11 show the result from three of the patients found to be negative. Lane 1 is a molecular weight marker -the distal marker runs at 100 bp and subsequent markers increase at 100 bp intervals. lation 15 and a cohort of myeloma patients. 16 The PCR assay used in this study was very sensitive and would not account for the discrepant results. The absence of a first round product in our study indicates the virus is present in very low copy number and this low viral load may require repeat testing of patient samples at distinct time-points for detection. Another possibility is that the population of myeloma patients studied may have differed and it would be interesting to compare the seroprevalence of antibodies to HHV-8 in the two groups.
In our view, the precise nature of the cell deemed to harbour the virus is not clear and the role of HHV-8 in the pathogenesis of myeloma remains unresolved. In addition to finding HHV-8 in 100% of long-term stromal cultures of myeloma patients, the same group of investigators has reported the 48% incidence in leukapheresis products and found viral DNA in the majority of peripheral blood cells after immunomagnetic selection with anti-CD68 and anti-CD83. 7 The long-term stromal culture cells identified as DC by immunophenotyping were not subject to functional analysis such as antigen presentation capacity. Likewise, the cell harbouring HHV-8 in the peripheral blood and leukapheresis product, including in our study, has not been clearly identified. The finding in our study of a positive leukapheresis sample in a patient whose monocyte-derived DC were negative suggests a non-monocytic reservoir. The B cell lymphotropism of HHV-8 points to the B cell as a potential source. However, the rare lineage-negative, HLA-DR-positive DC precursor in blood, distinct from cultured DC and possibly related to a bone marrow DC, cannot be excluded.
Therefore, while the association of HHV-8 with myeloma is biologically attractive, there is conflicting data and further study is required to clarify their precise relationship. Specific avenues of investigation would include a clear delineation of the infected cell in the marrow and blood and consideration of sample exchange between institutions to assess reproducibility of results. In the interim, there appears no reason to compromise the use of apheresis cells and their cultured progeny in the treatment of patients with myeloma.
